ACAD logo Acadia Pharmaceuticals : ACAD

ACAD

Stock Data

$27.15

Change up

$0.47 (1.76%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Acadia Pharmaceuticals Inc is a biopharmaceutical company based in San Diego, California, dedicated to developing and commercializing innovative medicines for central nervous system disorders and rare diseases. Its flagship product, NUPLAZID, treats hallucinations and delusions associated with Parkinson’s disease psychosis. Acadia is also advancing treatments for conditions like Rett Syndrome, schizophrenia, Prader-Willi syndrome, and Alzheimer’s disease psychosis, among others. The company, originally named Receptor Technologies, was founded in 1993 and emphasizes addressing unmet medical needs in neuropsychiatric conditions.

All Acadia Pharmaceuticals Articles

77 Articles

1 2 3 6

Featured Reads

Our top personal finance-related articles today. Your wallet will thank you later.